Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,764 total articles
BK Technologies has a tight float, clean balance sheet and improving margins. Recent contract wins and new radio platforms could be the catalyst to push earnings back into a higher-growth cycle. We outline an actionable mid-term (45 trading days) long trade with entry at $73.49, a $90 target and a $64 stop.
Nvidia’s business remains the epicenter of the AI infrastructure cycle: strong free cash flow, healthy margins and continuing data-center demand underpin a bullish mid-to-long-term trade. Valuation is rich but supported by earnings power. This trade recommends buying on strength/pullback with an entry at $227.00, a stop at $205.00 and a $320.00 tar…
Leonardo DRS (DRS) is uniquely positioned to benefit from renewed U.S. procurement and upgrade programs in sensors, battle networks, and autonomous systems. Solid Q4 results, low leverage, and recurring aftermarket demand support a mid-to-long-term long trade. Technicals are oversold, providing a cleaner entry for an upgrade-cycle replay.
HBR, the Canary Capital HBAR ETF, trades at $10.94 with a market cap of roughly $59.2m and bullish technicals. Low liquidity and rising short activity amplify upside on a momentum breakout. We lay out a mid-term (45 trading days) long trade with concrete entry, stop and target, plus catalysts and balanced risks.
Netflix's stock (NFLX) has cleared out a lot of optimism in 2026 and now trades at roughly $76.5. Fundamentals still support strong earnings growth, free cash flow generation of $11.15B, and an EV/EBITDA of ~8.3x. For disciplined traders, the risk/reward looks favorable over a 46-180 trading day horizon with a clear entry, stop, and target.
Nvidia remains the dominant supplier of high-performance AI accelerators. This trade idea buys into durable demand for GPUs in data centers and AI inference while using a defined stop to manage execution risk. The plan targets a re-rating toward prior highs if AI capacity growth continues, with explicit entry, stop, and target levels.
Ivanhoe Electric (IE) sits squarely at the intersection of copper demand and U.S. industrial policy. With signs that federal funding for domestic copper projects is gaining traction, IE's Santa Cruz-focused model and data/energy segments make it a compelling high-risk, high-reward swing trade. This note lays out a concrete trade plan, valuation fra…
SanDisk’s blockbuster quarter and multiyear NAND contracts have pushed flash pricing and customer commitment into the headlines. That news is bullish for data infrastructure spending broadly and, on balance, supports a tactical long in Western Digital (WDC). WDC’s recent earnings beat, product ramps for high-capacity nearline drives, reasonable fre…
Amazon's AI initiative (Leo) is a strategic lever that can convert massive infrastructure spending into higher margins and recurring revenue via AWS and advertising. The stock trades at ~20.8x earnings with a $2.77T market cap — reasonable for a company with AWS scale. This trade targets a mid-term re-rate as adoption and monetization of Leo accele…
Lennar (LEN) trades below book and near its 52-week low despite solid cash flow, low leverage, and a recent increase in Berkshire Hathaway interest. This trade idea buys a small starter position ahead of Q3 with a clear stop and target, aiming to capture a mean reversion to book and a post-earnings re-rating over the next 45 trading days.
Gold.com (GOLD) offers a compelling mid-term long setup despite headline risks to the gold market. Strong free cash flow ($206.9M), a reasonable P/E (~15-16), an enterprise value of $1.915B and diversified revenue streams (wholesale, direct-to-consumer, secured lending) give the company optionality if bullion softens. Technical momentum and managea…
Devon Energy (DVN) looks set to shift investor attention from financing and integration to upstream operations after completing the Coterra note exchanges. At roughly $48.76 today, shares trade on attractive fundamentals - low leverage, EV/EBITDA ~7.3, and free cash flow north of $1.4B - while technicals show room to run above recent SMA bands. Thi…
Puma Biotechnology (PBYI) is a small-cap oncology play where an established commercial product, NERLYNX, funds clinical and licensing optionality. At a market cap of roughly $487M and positive free cash flow, the setup favors a long-biased trade: collect time for pipeline progress and incremental commercial wins while downside is limited by a tangi…
Sony trades below its 52-week high with a $141.5B market cap, negative trailing PE but a healthy PB of 2.8 and meaningful exposure to high-margin content businesses. The firm's cross-segment IP engine - games, music, pictures, imaging and platform services - creates an earnings compounding flywheel that can re-rate as digital and AI trends accelera…
Charles Schwab is a high-quality, cash-generative brokerage with diversified revenue growth and a sensible valuation heading into late 2026. For existing holders the recommendation is to hold; for new capital, buy on a pullback to $101 with a $91 stop and a $122 target over the next 180 trading days. The trade rests on steady asset gathering, impro…
Frontline's fleet, outsized dividend, and elevated tanker market conditions are supporting cash returns and a re-rating opportunity. Combine a 6.8% yield, a low PE of 6.9, and bullish technicals and you get a tradeable long with clear entry, target and stop levels.
Nvidia's headline valuations and insider selling make for clickbait, but the fundamentals - $5.58T market cap, FCF of $127B, ROE >80% and a P/E near 29 - support a long trade from current levels. Technicals show bullish momentum with the stock above key EMAs while short interest is manageable. This trade plan targets $300 over a 180-trading-day hor…
Kodiak Sciences is a clinical-stage retinal biotech whose shares ripped to a 52-week high in April then dropped sharply. Fundamentals show the pipeline - especially tarcocimab - moving into late-stage programs and supporting potential regulatory filings across multiple indications. The market has punished the stock hard; at the current $34.80 price…
Bel Fuse's upsized $399M equity offering at $266 per share looked like a refashioned buyback in reverse: management sold stock at a premium, then deployed proceeds to pay down debt and close accretive deals (Enercon, dataMate). With $73M of free cash flow, a $3.6B market cap and clear M&A runway, this is a tactical long with a defined entry, stop a…
MoonLake Immunotherapeutics has a binary pipeline headline in sonelokimab, but the bull case doesn't require clinical dominance — only regulatory acceptance and a commercially viable label. With recent FDA nods, solid Week 40 Phase 3 signals in hidradenitis suppurativa (HS), a $200M offering that thickens the cash runway, and elevated short interes…
Hercules Capital (HTGC) currently trades at roughly a 45% premium to implied book value while offering a ~9.1% dividend yield and a market cap of $3.31B. We believe that durable venture lending originations, recent big-ticket financings and an improving technical setup justify paying up for HTGC. This trade plan targets $21.50 over a 180-trading-da…
Hasbro's Wizards of the Coast franchise is materially changing the growth profile of the company. With Magic: The Gathering and Dungeons & Dragons powering double-digit segment growth, Hasbro's current valuation - roughly $12.7B market cap and mid-teens P/E - looks vulnerable to a positive re-rating if execution holds. This trade idea buys into tha…
WesBanco (WSBC) trades at attractive multiples (P/E ~12, P/B ~1.02) with a healthy dividend ($0.38 quarterly) and strong free cash flow. We recommend a long trade sized to risk appetite with entry at $41.01, stop at $37.00 and target at $47.00 over a long-term horizon (180 trading days). The thesis rests on solid profitability and capital returns; …
KBR is a play on durable government/defense revenues, proprietary sustainable-process technology, and an upcoming spin-off (Trinzic) that should unlock value. At roughly $36.71 today, KBR trades at ~11x EPS with a $4.6B market cap and $23B backlog. We outline a long trade with concrete entry, targets and stop, horizon, and clear risks.
Novartis dropped sharply after pelacarsen failed its Phase III goal. The headline is painful, but the company’s $284B market cap, $9.7B free cash flow, low leverage and a diversified portfolio - including radioligand therapy exposure - provide a foundation to absorb two near-term setbacks. This trade idea outlines a disciplined long entry, stop, an…
